This is the second public scrutiny of a M&A deal by the Competition Commission of India (CCI) after Ranbaxy-Sun Pharma merger.
The comments with respect to the Holcim-Lafarge deal need to be submitted to the CCI (Competition Commission of India) within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the regulator said, adding that it would not consider 'unsubstantiated objections' to the deal.
The deal between Holcim and Lafarge, both of which have good presence in India, was announced in April this year.
There have been concerns that the transaction could raise anti-competitive issues in the Indian market.
Also Read
Swiss major Holcim has controlling stakes in India's two leading cement makers - ACC Ltd and Ambuja Cements.
While announcing the deal in April, it was said that after a strategic optimisation of the portfolio through a pro-active divestment process, in anticipation of regulatory requirements, LafargeHolcim would occupy complementary positions.
Holcim and Lafarge have submitted to the Commission that the proposed transaction "would not lead to removal of a vigorous and effective competitor" as the most aggressive players in this business segment are localised players.